Search Clinical Trials in the European Union

Duration
Visits
Monitoring phase (IV)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 552 trials

Intra-Hepatic Cholangiocarcinoma: New Treatment Approaches

We are studying a combination of treatments for patients with inoperable intra-hepatic cholangiocarcinoma. The goal is to see if these treatments can improve survival and quality of life.

Non-resectable Cholangiocarcinoma>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Type 2 Diabetes: Finerenone and SGLT2 Inhibitors

We are studying the effects of a new treatment combining finerenone with SGLT2 inhibitors for people with type 2 diabetes. The goal is to see if this combination improves heart and kidney health.

Type 2 DiabetesChronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNephrology

Spinal Muscular Atrophy: Risdiplam Treatment Study

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have received gene therapy. This research aims to see if early treatment can improve their condition.

Spinal Muscular Atrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Antithrombotic Therapy After Aortic Valve Implantation

We are studying whether a personalized, CT-guided antithrombotic therapy can better reduce serious heart and bleeding events compared to standard treatment in patients after transcatheter aortic valve implantation.

Aortic Valve StenosisMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Guselkumab for Active Psoriatic Arthritis Axial Disease

We are studying whether guselkumab can help reduce symptoms in people with active psoriatic arthritis axial disease who have not been treated before. Participants will receive either the medication or a placebo.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Non-Transfusion-Dependent Thalassemia: Luspatercept Treatment

We are studying whether luspatercept can improve brain oxygen levels and blood flow in patients with non-transfusion-dependent thalassemia. The trial also looks at its effects on cognitive function and heart health.

Non-transfusion Dependent Beta-Thalassemia6-12 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHematologyNeurology

High Cardiovascular Risk: Rosuvastatin vs. Combination Therapy

We are studying whether high-intensity rosuvastatin or a combination of rosuvastatin and ezetimibe can effectively lower cholesterol in patients at high or very high risk for heart disease. The goal is to see if these treatments help achieve specific cholesterol targets.

High Cholesterol≤3 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Heart Failure: Stopping Medication After Cardiac Resynchronization Therapy

We are studying the effects of withdrawing medication in patients who have improved heart function after cardiac resynchronization therapy. This trial will help us understand the safety and changes in heart health when treatment is stopped.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

HIV and Liver Health: Doravirine Study

We are exploring how the medication Doravirine affects liver fat and fibrosis in people living with HIV who have liver issues. This study aims to see if switching to Doravirine improves liver health over time.

Human Immunodeficiency Virus (HIV)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesHepatologyInfectious DiseasesInternal Medicine

Lung Cancer Treatment Comparison: Atezolizumab vs. Pembrolizumab

We are studying two treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma to see which one may improve survival. This trial compares atezolizumab with carboplatin and nab-paclitaxel against pembrolizumab with platinum and pemetrexed.

Metastatic Lung Adenocarcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyPulmonology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

S. aureus Bacteremia: Cloxacillin Dosing Study

We are investigating whether kidney function can help identify patients who may need adjusted doses of cloxacillin. This study aims to ensure safer and more effective treatment for those with S. aureus bacteremia.

Staphylococcus aureus BacteremiaMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesNephrology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Blood Pressure Response: Multi-Omics Study

We are exploring how specific biomarkers can predict the effectiveness of blood pressure medications for individuals. This study aims to improve treatment personalization and understand potential side effects.

Essential Hypertension3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementCardiologyInternal Medicine

COPD Treatment: Understanding ICS Response

We are studying how different eosinophil levels affect the response to inhaled corticosteroids in COPD patients. This research may help personalize treatment strategies for better management of the disease.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyPulmonology

Heart Health: Adenosine Dose Study

We are investigating how different doses of adenosine affect blood flow in the heart for healthy individuals and patients with coronary artery disease. This study aims to understand if the response varies based on health status.

Chronic Ischemic Heart DiseaseMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Osteoarthritis in the Thumb: Comparing Treatments

We are studying whether steroid injections are more effective than saline injections and occupational therapy for painful thumb osteoarthritis. The goal is to improve pain, function, and overall quality of life.

Osteoarthritis of the Thumb>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesOrthopedics and TraumatologyRheumatology

Coronary Disease: Tirzepatide Study

We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.

Overweight and Obesity1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinology

Ofatumumab in Breast Milk: A Study for Lactating Women with MS

We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.

Multiple Sclerosis Relapse1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsNeurology

Perianal Crohn’s Disease: FAPi-PET Imaging Study

We are exploring whether a new imaging method can help visualize and measure healing in fistulas for patients with perianal Crohn’s disease. This study may also help predict how well treatments are working.

Crohn's DiseaseFistulizing Crohn's Disease≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine